These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19929178)

  • 1. Regulation of p53--insights into a complex process.
    Boehme KA; Blattner C
    Crit Rev Biochem Mol Biol; 2009; 44(6):367-92. PubMed ID: 19929178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling to p53: breaking the posttranslational modification code.
    Appella E; Anderson CW
    Pathol Biol (Paris); 2000 Apr; 48(3):227-45. PubMed ID: 10858956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of protein Citrullination through p53/PADI4 network in DNA damage response.
    Tanikawa C; Ueda K; Nakagawa H; Yoshida N; Nakamura Y; Matsuda K
    Cancer Res; 2009 Nov; 69(22):8761-9. PubMed ID: 19843866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of p53 responses by post-translational modifications.
    Xu Y
    Cell Death Differ; 2003 Apr; 10(4):400-3. PubMed ID: 12719715
    [No Abstract]   [Full Text] [Related]  

  • 5. Differential post-translational modification of the tumour suppressor proteins Rb and p53 modulate the rates of radiation-induced apoptosis in vivo.
    Wallace M; Coates PJ; Wright EG; Ball KL
    Oncogene; 2001 Jun; 20(28):3597-608. PubMed ID: 11439323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The complex interactions of p53 with target DNA: we learn as we go.
    Kim E; Deppert W
    Biochem Cell Biol; 2003 Jun; 81(3):141-50. PubMed ID: 12897847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?
    Olsson A; Manzl C; Strasser A; Villunger A
    Cell Death Differ; 2007 Sep; 14(9):1561-75. PubMed ID: 17627286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53.
    Albrechtsen N; Dornreiter I; Grosse F; Kim E; Wiesmüller L; Deppert W
    Oncogene; 1999 Dec; 18(53):7706-17. PubMed ID: 10618711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage.
    Jimenez GS; Bryntesson F; Torres-Arzayus MI; Priestley A; Beeche M; Saito S; Sakaguchi K; Appella E; Jeggo PA; Taccioli GE; Wahl GM; Hubank M
    Nature; 1999 Jul; 400(6739):81-3. PubMed ID: 10403253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
    Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
    Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of DNA damage recognition and nucleotide excision repair: another role for p53.
    Ford JM
    Mutat Res; 2005 Sep; 577(1-2):195-202. PubMed ID: 15927209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the E6-p53 interaction in the molecular pathogenesis of HPV.
    Thomas M; Pim D; Banks L
    Oncogene; 1999 Dec; 18(53):7690-700. PubMed ID: 10618709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation-acetylation interplay activates p53 in response to DNA damage.
    Ivanov GS; Ivanova T; Kurash J; Ivanov A; Chuikov S; Gizatullin F; Herrera-Medina EM; Rauscher F; Reinberg D; Barlev NA
    Mol Cell Biol; 2007 Oct; 27(19):6756-69. PubMed ID: 17646389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-translational modification of p53 and the integration of stress signals.
    Meek DW
    Pathol Biol (Paris); 1997 Dec; 45(10):804-14. PubMed ID: 9769944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Death squads enlisted by the tumour suppressor p53.
    Michalak E; Villunger A; Erlacher M; Strasser A
    Biochem Biophys Res Commun; 2005 Jun; 331(3):786-98. PubMed ID: 15865934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 regulation and function in normal cells and tumors.
    Liu Y; Kulesz-Martin M
    Medicina (B Aires); 2000; 60 Suppl 2():9-11. PubMed ID: 11188940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation.
    Nip J; Strom DK; Eischen CM; Cleveland JL; Zambetti GP; Hiebert SW
    Oncogene; 2001 Feb; 20(8):910-20. PubMed ID: 11314026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses.
    Jimenez GS; Khan SH; Stommel JM; Wahl GM
    Oncogene; 1999 Dec; 18(53):7656-65. PubMed ID: 10618705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53.
    Kim E; Rohaly G; Heinrichs S; Gimnopoulos D; Meissner H; Deppert W
    Oncogene; 1999 Dec; 18(51):7310-8. PubMed ID: 10602486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association.
    Sachchidanand ; Resnick-Silverman L; Yan S; Mutjaba S; Liu WJ; Zeng L; Manfredi JJ; Zhou MM
    Chem Biol; 2006 Jan; 13(1):81-90. PubMed ID: 16426974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.